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Abstract
Background: The enteric nervous system (ENS) is entirely derived from neural crest and its normal development is regulated
by specific molecular pathways. Failure in complete ENS formation results in aganglionic gut conditions such as
Hirschsprung’s disease (HSCR). Recently, PROKR1 expression has been demonstrated in mouse enteric neural crest derived
cells and Prok-1 was shown to work coordinately with GDNF in the development of the ENS.
Principal Findings: In the present report, ENS progenitors were isolated and characterized from the ganglionic gut from
children diagnosed with and without HSCR, and the expression of prokineticin receptors was examined. Immunocyto-
chemical analysis of neurosphere-forming cells demonstrated that both PROKR1 and PROKR2 were present in human
enteric neural crest cells. In addition, we also performed a mutational analysis of PROKR1, PROKR2, PROK1 and PROK2 genes
in a cohort of HSCR patients, evaluating them for the first time as susceptibility genes for the disease. Several missense
variants were detected, most of them affecting highly conserved amino acid residues of the protein and located in
functional domains of both receptors, which suggests a possible deleterious effect in their biological function.
Conclusions: Our results suggest that not only PROKR1, but also PROKR2 might mediate a complementary signalling to the RET/
GFRa1/GDNF pathway supporting proliferation/survival and differentiation of precursor cells during ENS development. These
findings, together with the detection of sequence variants in PROKR1, PROK1 and PROKR2 genes associated to HSCR and, in some
cases in combination with RET or GDNF mutations, provide the first evidence to consider them as susceptibility genes for HSCR.
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Introduction
The enteric nervous system (ENS) is composed of a large
number of neurons and glia, which are organised into intercon-
nected ganglia distributed throughout the gastrointestinal tract. It
is originated from neural crest cells (NCCs), that invade the foregut
mesenchyme during embryogenesis and migrate in a rostrocaudal
direction to extensively colonize the entire length of the gut [1].
Failure in these processes results in aganglionic gut conditions,
such as Hirchsprung disease (HSCR) in humans. HSCR, with an
incidence of 1:5000 live births, is the most common developmental
disorder of the ENS, characterized by its incomplete formation
and the absence of enteric ganglia in a variable segment of distal
bowel. This leads to peristaltic misregulation and tonic contraction
within the affected gut, causing intestinal obstruction [2]. HSCR
most commonly presents sporadically and displays a complex
pattern of inheritance with low, sex-dependent penetrance and
variable expression [3].
The genetic complexity observed in HSCR could be explained
by the complex nature of ENS development, which is regulated by
an ever-increasing range of molecules and signalling pathways
involving both the NCCs and intestinal environment [4]. Develop-
mental biology studies have identified that the RET/GFRa1/
GDNF signalling pathway is the most critical player for enteric
neurogenesis and the proper expression of these proteins have
been demonstrated to be crucial for the normal development
of the ENS. Recently, it was shown that Prokineticin-1 (Prok1)
is expressed in the mucosa and mesenchyme of the mouse em-
bryonic gut during ENS development and promotes the survival/
proliferation and differentiation, but not migration, of enteric
NCCs [5]. Prok1 crosstalks with GDNF/Ret signaling and
probably provides an additional layer of signaling refinement to
maintain proliferation and differentiation of enteric NCCs [6].
Prokineticins (PROK1 and PROK2) belong to the AVIT
protein family, a recently identified family of cysteine-rich secreted
protein that share the identical amino terminal sequence crucial
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for their biological activities [7,8]. These proteins are known to
bind and activate two closely related Gprotein-coupled receptors,
PROKR1 and PROKR2, leading to the mobilization of calcium,
the stimulation of phosphoinositide-3-kinase turnover, and the
activation of the mitogen activated protein kinase (MAPK) sig-
nalling pathway [9–11]. Prokineticins were first identified in the
gastrointestinal tract as a potent agents mediating smooth muscle
contraction [7]. However, they also act as survival/mitogenic
factors for endothelial cells, neurons, lymphocytes and hemato-
poietic stem cells.
This report provides the first evidence that PROKR2 could be
involved in ENS development. We show that not only PROKR1,
as it was previously suggested [5,6], but also PROKR2 are present
in human enteric NCCs since both receptors are expressed in ENS
progenitors isolated from ganglionic gut samples of patients
diagnosed with HSCR. In addition, we have also performed a
mutational analysis of PROKR1, PROKR2, PROK1 and PROK2
genes in a cohort of HSCR patients, evaluating them for the first
time as susceptibility genes for the disease.
Results
Characterization of Cell Cultures
Postnatal ganglionic gut tissues from HSCR patients and
controls were dissociated into near single cell suspension and
plated in a medium suplemented with EGF, bFGF and GDNF
that promotes the growth of isolated ENS progenitors. Over the
next 3–4 days, floating neurospheres could be observed (Figure 1).
After multiple (3–4) subcultures, part of the neurospheres derived
cells still generated new neurospheres with similar characteristics,
which indicates the existence of cells with self-renewal properties.
To characterize the cells that form the neurospheres, they were
immunostained using a neural stem cells marker (Nestin), neuronal
marker (TuJ1), glial markers (GFAP, S100) and smooth muscle
marker (SMA) (Figure 2). As a result, neurospheres were con-
stituted by Nestin-positive cells (77%62), and most of them also
contained cells that expressed the neuronal marker (11%63)
(Figure S1). However, staining with antibodies against S100 and
SMA showed only a small fraction of positives cells (3%61 and
2%60.4, respectively), while immunofluorescence for GFAP
demonstrated a lack of reactivity. RET was also expressed by
neurosphere cells and confocal analysis revealed the presence of
this receptor in all Nestin-positive neurosphere cells. Taken
together, these results suggest that the neurosphere-like bodies
contained a mixture of neural and non-neural cells representing
different stages of differentiation. In addition, no differences were
observed between neurospheres derived from ganglionic gut from
children with or without HSCR.
Human ENS-Derived Cells Expressed PROKR1 and
PROKR2 receptors ‘‘in vitro’’
The expression of prokineticins receptors in human neuro-
spheres was examined. Immunocytochemical detection using
specific antibodies revealed that both receptors, PROKR1 and
PROKR2, were expressed in floating neurospheres obtained from
the ganglionic gut from HSCR patients (Figure 3A and B, Figure
S2). Cells PROKR1 and PROKR2 positives were also Nestin
positive, which demonstrate that both receptors are expressed by
undifferentiated enteric neural precursor cells (Figure 3C and E).
In addition, we have also observed co-expression of PROKR1
with TuJ1 (Figure 3D), suggesting that this receptor is still
expressed in cells already committed to neuronal fate. Analysis of
mRNA by RT-PCR was also performed to confirm the presence
of both PROKR1 and PROKR2 transcripts in human ENS-
derived cells (Figure 4). cDNA from the neuroblastoma cell line
SK-N-MC and human endometrium tissue were used as positive
control and cDNA from lymphocytes as negative control (data not
shown).
Mutational analysis
The mutational screening of PROKR1, PROK1, PROKR2 and
PROK2 genes revealed a total of 13 heterozygous sequence
variants in 16 unrelated HSCR patients (Table 1, Figure 5). Four
of those variants, detected in PROKR2, had been previously
reported as mutations associated to Kallmann Syndrome [12–14].
However, no clinical signs or symptoms of Kallmann syndrome
were observed in HSCR patients carrying PROKR2 variants. Only
the variants R85C in PROKR2 and the novel G54G in PROK1
were present in control individuals, while the remaining variants
were absent in 150 control individuals tested. In addition, when
genomic DNA from other family member was available, we have
also analysed them and we found that all the variants had been
inherited from one of their parents. Five out of the 16 patients
carrying these changes (32%) also presented a mutation in the
coding sequence of RET or GDNF [15,16]. No mutations were
detected in any other HSCR related gene, namely NRTN, ARTN,
PSPN, NTF3, NTRK3, EDNRB, EDN3, SOX10 or PHOX2B [16–
21, unpublished results].
In order to establish the pathogenic relevance of those variants,
we have performed in silico analysis using different bioinformatic
tools. Based on the conserved status of the sequence and the physical
properties of amino acids, Polyphen and SIFT programs predicted
Figure 1. Generation of neurospheres from human neural precursors cells isolated from ENS. Phase contrast images showing
characteristic neurospheres generated from freshly dissociated HSCR ganglionic gut tissue cells after 7 days in culture (A, B). Floating neurospheres
were seeded onto coverslip and grown adhered using the same culture conditions (C). Scale bars 50 mm.
doi:10.1371/journal.pone.0023475.g001
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that, with the exception of the variant V297I in PROKR2, all the
changes could generate a probably damaged protein. Moreover,
DiANNA software also predicted that the inclusion of additional
cysteine residues at positions 85 and 268 in PROKR2 could lead to
a different distribution of the disulfide bonds in comparison to
the wild type protein, that may induce a change in the three-
dimensional structure of the protein. Finally, after analysis using
ScanProsite interface we observed that the residues R85, R268,
P290, Y292 and V297 in PROKR2 were distributed in the
functional domains of the receptor, suggesting that an amino acid
change at these position could affect its function.
Discussion
Several studies have demonstrated that undifferentiated precur-
sors cells are present within the gastrointestinal tract not only during
embryonic development but also into early postnatal life [22–26]. In
the present report, ENS progenitors were isolated from the
ganglionic gut from childrens diagnosed with or without HSCR,
using full-thickness gut resection specimens or gut biopsy samples,
respectively. Immunocytochemical analysis of neurosphere-forming
cells showed that the majority of the ENS progenitors in culture
were undifferentiated neural stem cells, expressing most of them
the RET receptor. A subset of neuronal cells was also observed,
including TuJ1 positive cells co-expressing nestin that still retain
multipotent characteristics but are competent to differentiate along
the differentiated phenotype. However, only a small fraction of
S100 positives cells could be identified, indicating an initial step for
glial lineage differentiation in the neurospheres. In this sense, it has
been demonstrated that neural diversity lineages strongly depends
on the cell-intrinsic differences in their responsiveness to factors and
gut NCCs are more responsive to neurogenic factors than gliogenic
factors, giving rise primarily to neurons [27]. Moreover, diverse
environmental conditions was suggested to play a role in regulate
differentiation, and the neurosphere microenvironment in culture
could be not appropriate enough for the differentiation of glial cells
[24,28]. On the other hand, it was possible to dissociate primary
derived neurospheres and generate secondary and tertiary neuro-
spheres, supporting the presence of self-renewing progenitors in
culture [24].
Using these neurospheres cultures, we investigated the expres-
sion of PROKR1 and PROKR2 in human enteric NCCs. Our
results show that not only PROKR1 is present in neural stem cells
and neuronal precursors, but also PROKR2 receptor is observed.
PROKR1 expression was previously demonstrated in mouse
enteric neural crest derived cells and Prok-1 was shown to work
coordinately with GDNF in the development of the ENS [5,6].
Firstly, both GDNF and Prok-1 share common downstream
elements, prominently the MAPK and Akt pathways, which
provide multiple points of insertions between these two factors and
lead them to exhibit similar biological functions [5]. In addition,
GDNF potentiate the proliferative and differentiation effects of
Prok-1 by up-regulating PROKR1 expression in enteric NCCs
[6]. This functional redundancy of PROKR1/Prok-1 and RET/
GFRa1/GDNF signalling supports the idea that Prok-1/
PROKR1 provides a compensatory pathway to ensure the proper
development of ENS.
On the other hand, our results show for the first time the
expression of PROKR2 in human enteric neural crest derived cells,
which confirm that expression profiles of prokineticin receptors in
mouse are slightly different from that in human [29]. We suggest
that PROKR2 would have a relevant role by inhibiting apoptosis of
enteric neuronal precursors, as it was previously described in neural
crest-derived neuroblastoma cells [30]. Therefore, PROKR2 could
mediate neuronal protection or survival not only in the central
nervous system [31], but also during the ENS development.
According to that, PROKR1, PROK1, PROKR2 and PROK2
were evaluated as susceptibility genes for HSCR, based on the
Figure 2. Characterization of neurospheres from human neural
precursors cells isolated from ENS. Confocal microscopy images of
floating neurospheres inmunostained with antibodies against Nestin
(blue), TuJ1 (green), SMA (green), S100 (red) and RET (red) and counter-
stained with DAPI (4,6-diamidino-2-phenylindole). Scale bars 25 mm.
doi:10.1371/journal.pone.0023475.g002
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etiopathogenesis of the disease. Several missense variants in
PROKR1, PROK1 and PROKR2 genes were detected, most of them
affecting highly conserved amino acid residues of the protein and
located in functional domains of both receptors, which suggests a
possible deleterious effect in their biological function. It is also worth
of mentioning that four of the PROKR2 mutations were previously
described associated to Kallmann syndrome [12–14], another
congenital disorder defined by hypogonadotropic hypogonadism
and olfactory abnormalities, often associated with renal agenesis
and other developmental defects. In these patients, hypogonadism is
due to a failure of embryonic migration of gonadotropin-releasing
hormone-synthesizing neurons from the olfactory epithelium to the
forebrain, and insufficient prokineticin signalling through PROKR2
seems to play a critical role. The analysis of the functional effect of
these mutations by measuring intracellular calcium release upon
ligand binding has demonstrated a decreased signalling activity of
the receptor [32]. Specifically, P290S impaired cell surface-
targeting of the receptor and R85C, R85H and R268C presumably
impaired G protein-coupling. However, when both the wild-type
and mutant receptors were co-expressed, none of the mutant
receptors affected the properly signalling activity provided by the
wild-type receptor. Therefore, these results argue against a
dominant negative effect of these mutations in vivo, supporting
the current hypothesis of an autosomal recessive inheritance or
oligogenic model previously reported since heterozygous mutations
are not sufficient to cause Kallmann syndrome. In this sense, our
results suggest that those variants detected in the genes encoding
prokineticins and their receptors may also contribute to the HSCR
susceptibility acting together with mutation in additional different
genes, according to the additive complex model of inheritance
accepted for the disease. Interestingly, we observed that mutations
in RET proto-oncogene or GDNF are frequently associated to the
presence of sequence variants in these genes in our cohort of HSCR
patients, contributing to the manifestation of the more severed
Figure 3. PROKR1 and PROKR2 expression in neurosphere cultures. Confocal microscopy images of floating neurospheres (A, B) and
adhered neurosphere derived cells as described in Figure 1C (C–E) immunostained with antibodies against PROKR1 (red), PROKR2 (red), Nestin (blue)
and TuJ1 (green). Scale bars 25 mm.
doi:10.1371/journal.pone.0023475.g003
Figure 4. RT-PCR analysis of PROKR1 and PROKR2 expression
in human ENS-derived cells. Total RNA was isolated from neuro-
spheres (NS) and both PROKR1 and PROKR2 transcripts were detected
by RT-PCR. cDNA from the neuroblastoma cell line SK-N-MC and human
endometrium tissue (END) were used as positive control. Ribosomal 18S
was used as the internal control.
doi:10.1371/journal.pone.0023475.g004
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phenotypes. In summary, we show PROKR1 and PROKR2
expression in human enteric NCCs, which suggests that both
prokineticin receptors might mediate a complementary signalling to
the RET/GFRa1/GDNF pathway supporting proliferation/sur-
vival and differentiation of precursor cells during ENS development.
These results, together with the detection of sequence variants in
PROKR1, PROK1 and PROKR2 genes associated to HSCR and
in some cases in combination with RET or GDNF mutation,
provide the first evidence to consider them as susceptibly genes for
HSCR.
Materials and Methods
Ethical approval
Approval from the Hospital Universitario Virgen del Rocı´o of
Sevilla Health Ethics Subcommittee and fully written informed
consent were obtained from all the participants for surgery, clinical
and molecular genetic studies. The study conformed to the tenets
of the declaration of Helsinki, as well as the requirements
established in the Spanish law (Ley 14/2007, from 3 July 2007,
‘‘Ley de Investigacio´n Biomedica’’).
Table 1. PROKR1, PROK1, PROKR2 sequence variants detected in HSCR patients.
Gene
Nucleotide
Change
Amino Acid
Change
Familial/
Sporadic Inheritance
Segment
lenght In silico analysis
Mutations in RET or
other HSCR genes
Novel/Previously
reported
PROKR1 c.387C.T p.S129S Sporadic Not Available S-HSCR No effect Novel
c.1062A.T p.K354N Sporadic Father S-HSCR Possibly damaging Novel
c.1121G.A p.L374L P1: Sporadic
P2: Familial
P1: Not Available
P2: Mother
TCA No effect Novel
PROK1 -45G.A Sporadic Mother S-HSCR No effect P953L in RET from mother Novel
c.142C.T p.R48W Sporadic Not Available L-HSCR Probably damaging rs62623571
c.162G.T P.G54G* P1: Sporadic
P2: Sporadic
P1: Mother
P2: Father
TCA
S-HSCR
No effect P1: P992L in RET de novo Novel
PROKR2 c.202G.A p.G68S Sporadic Mother L-HSCR Probably damaging Novel
c.253C.T p.R85C* P1: Sporadic
P2: Familial
P1: Father
P2: Father
S-HSCR
S-HSCR
Probably damaging Cole LW, 2008
c.254G.A p.R85H Sporadic Mother NA Probably damaging V145L in RET from mother Dode´ C, 2006
c.802C.T p.R268C Sporadic Father TCA Probably damaging G593X in RET from father rs78861628
c.868C.T p.P290S Sporadic Mother L-HSCR Probably damaging R93W in GDNF from father Dode´ C, 2006
c.876 C.T p.Y292Y Sporadic Father S-HSCR No effect Novel
c. 889G.A p.V297I Sporadic Father S-HSCR Tolerated Novel
S-HSCR: short segment; L-HSCR: long segment; TCA: total colonic aganglionosis; NA: not available data.
*Sequence variants detected in normal controls.
doi:10.1371/journal.pone.0023475.t001
Figure 5. Schematic representation of PROKR1, PROK1, PROKR2 and PROK2 proteins. Distribution of the missense variants identified in
our cohort of HSCR patients with respect to the predicted proteins structure using the SOSUI secondary structure prediction program.
doi:10.1371/journal.pone.0023475.g005
PROKR1 and PROKR2 in Human ENS Progenitors
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23475
Generation of Human Neurosphere
Human postnatal tissues of ganglionic full-thickness gut were
obtained from 13 HSCR neonates (3 female, 10 male) undergoing
gut resection surgery at Hospital Universitario Virgen del Rocı´o in
Sevilla. In addition, 5 endoscopic gut biopsy samples (1 female, 4
male) from patients investigated for other gastrointestinal disorders
were used as controls. From both HSCR patients and controls, age
were comprised between 6 and 24 months.
All the samples were incubated in a solution of 0,26 mg/mL
Trypsin Collagenase, 5 mg/mL Dispase, 0,28 mg/mL Hyaluron-
idase, 3,3 mg/mL Elastase and 0,6 mg/mL Collagenase in
phosphate-buffered saline (PBS) for up to 30 minutes at 37uC.
Digested tissue was triturated and washed, and the cells were
cultured in 6-wells ultra-low attachment cluster plate. The culture
medium was Dulbecco’s modified Eagle medium (DMEM; 1 mg/
mL Glucose) containing 100 U/mL penicillin, 100 g/mL strep-
tomycin, supplemented with 2 mM L-glutamine (Gibco, Life
Technology, California, USA), 0.05 mM 2-mercaptoethanol, 1%
(v/v) N1 (Sigma Aldrich, Poole, Dorset, UK), 10% (v/v) Human
serum, 20 ng/mL basic fibroblast growth factor (bFGF), 20 ng/
mL epidermal growth factor (EGF) and 10 ng/mL glial cell
derived neurotrophic factor (GDNF) (Peprotech, London, UK).
Subcultures were performed every 7 days and experiments were
performed between passage 1 and 3.
Immunocytochemistry
For immunocytochemical studies, neurospheres were seeded
onto coverslips fibronectin-poly D lysine coated and fixed with
4% (wt/vol) paraformaldehyde in 0.1 M PBS. The primary
antibodies used were b-III-tubulin (TuJ1) (1:2000; Promega
Corporation, Madison), Nestin (1:200; Santa Cruz Biotechnolo-
gy, Inc.), glial fibrillary acidic protein (GFAP) (1:1000; Dako),
S100B (1:200; Dako), a-Smooth Muscle Actin (aSMA) (1:400;
Sigma Aldrich), RET receptor (1:250; Santa Cruz Biotechnology),
Prokineticin Receptor 1 (PKR1) (1:500) and Prokineticin Receptor
2 (PKR2) (1:1000); (Lifespan Biosciences, Inc., Seattle, WA). The
secondary antibodies used were labeled with Alexa Fluor 568 (Life
Technology), Cy5 and Cy2, (Jackson Immuno Research Labora-
tories, Inc., West Grove, PA). The coverslips were mounted on
slides with Fluoro-Gel (EMS, Hatfield, PA, USA) and fluorescent
signals were detected using a Leica Spectra confocal microscope. All
of the secondary antibodies were adsorbed against several species to
prevent undesired cross-reactions. Omission of primary antibodies
resulted in no detectable staining in all cases.
RT-PCR
Total RNA was isolated from neurospheres and SK-N-MC cells
[32] using High Pure RNA Isolation Kit (Roche Diagnostics,
Mannheim, Germany), according to manufacturer instructions.
1 mg of RNA was reverse-transcribed using SuperScriptTM RNA
Amplification System and PCR reactions were performed using
specific primers: PROKR1-F 59-TGAGGATGTGACCAAT-
TCCA-39, PROKR1-R 59-GATGGTGAAGCCGTAGAAGG-
39, PROKR2-F: 59-CGGCAGCTCTCCTGGGAGCATGGC-
39; PROKR2-R: 59-CGTCTGGAACCCAGGGACTGCC -39
and 18S-F: 59-CAGCCACCCGAGATTGAGCA-39, 18S-R: 59-
TAGTAGCGACGGGCGGTGTG-39. The estimated sizes of
RT-PCR products were 769 for PROKR1,432 bp for PROKR2
and 253 for 18S.
Mutational analysis
A total of 230 patients diagnosed with HSCR (23% female, 77%
male) at Hospital Universitario Virgen del Rocı´o in Sevilla were
included in the mutational analysis. 208 were sporadic cases, while
22 were familial cases belonging to 13 different families. In
addition, we have also analyzed a group of 150 normal controls
comprising unselected, unrelated, race, age, and sex-matched
individuals.
Genomic DNA was extracted from peripheral blood leukocytes
from patients and healthy controls using standard protocols. The
mutational screening of the complete coding sequence and intron/
exons boundaries of PROKR1, PROK1, PROKR2 and PROK2 was
carried out by denaturing high performance liquid chromatography
(dHPLC) in a WAVE DNA Fragment Analysis system (Transge-
nomic, Omaha, NE). In addition, those exons with aberrant profiles
were subjected to sequence analysis using an ABI PrismH3730
Genetic Analyzer (Applied Biosystem, Foster City, CA) and the
SeqScapeH v2.5 software (Applied Biosystem, Foster City, CA).
When a novel change was detected, the appropriated DNA
fragment was also screened in a group of 150 normal controls, in
order to determine that such variant is not just a common
polymorphism never previously described.
Bioinformatic tools
Novel variants located within the non-coding region were
submitted to several Splice Sites and Transcription Factors Binding
sequences prediction interfaces such as http://www.fruitfly.org/
seq_tools/splice.html; http://www.fruitfly.org/cgi-bin/seq_tools/
promoter.pl; and http://www.ebi.ac.uk/asd-srv/wb.cgi. To predict
the putative pathogenic role of a novel variant at the protein
sequence level, we selected the SIFT, Polyphen and DiANNA tools
(http://blocks.fhcrc.org/sift/SIFT.html, http://genetics.bwh.har-
vard.edu/pph/, http://clavius.bc.edu/,clotelab/DiANNA/). The
PROKR1 and PROKR2 protein sequences were submitted to
ScanProsite (http://expasy.org/tools/scanprosite/) to scan for the
occurrence of patterns, profiles and motifs stored in the PROSITE
database.
Supporting Information
Figure S1 Histogram showing distribution of Nestin+
cells, TuJ1+ cells, S-100+ cells and SMA+ cells in neuro-
spheres. At least 3 different preparations were assessed for each
marker and 3–6 neurospheres were analysed per coveslip (,1.300
cells). Data are presented as percentage of each phenotype with
the standard error of the mean.
(TIF)
Figure S2 Confocal microscopy images of floating
neurospheres immunostained with antibodies against
Nestin (blue), TuJ1 (green), PROKR1 (red), PROKR2
(red) and counterstained with DAPI (4,6-diamidino-2-
phenylindole). Scale bars 25 mm.
(TIF)
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